Pharma ind seeks govt assistance on takeover concerns

Image
Press Trust of India New Delhi
Last Updated : Jan 21 2013 | 12:29 AM IST

Concerned over the recent takeover of some firms by Multi National Companies (MNCs), the domestic pharmaceutical industry has asked the government to protect and promote it by making available funds for research and development.

In a letter to the department of pharmaceuticals, Indian Pharmaceutical Alliance (IPA) has said lack of available funding is the main reason for the recent spurt in the sale of stakes in domestic companies.

"In view of your concern and interest in promoting growth and development of pharmaceutical industry, we urge you to examine this phenomenon and consider appropriate funding mechanism to protect and promote the domestic industry," IPA said.

Since June last year, multinationals have acquired six drug comopanies, including the Rs 22,000 crore takeover of Ranbaxy Laboratories by Japanese drug maker Daiichi Sankyo.

According to industry experts, drying up of product pipelines of MNCs are forcing them to buy up Indian firms to a get a hold on the generic business globally. Of late, there have been reports of majors like Pfizer scouting the Indian market for acquisitions.

The association said the sell-outs have highlighted the need for an "appropriate funding mechanism" to meet the challenges faced by Indian pharma companies.

Also, these have exposed the limitations of the current policy framework of providing weighted deduction for R&D and meagre amounts granted under Market Development Assistance (MDA) programme, it said.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 06 2009 | 5:48 PM IST

Next Story